{"date":"2025-09-05","count":10,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-7827-2025-09-05-1759-1rjah9o","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2025-09-05","time":"17:59:22","subject":"公告本公司控股子公司FBD Biologics Limited依約收到上海復宏漢霖生物技術股份有限公司支付第二階段HCB101新藥授權簽約金600萬美元，合計已收足1,000萬美元。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2025-09-05 17:59，「公告本公司控股子公司FBD Biologics Limited依約收到上海復宏漢霖生物技術股份有限公司支付第二階段HCB」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-09-05-1640-1kbupvl","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-09-05","time":"16:40:08","subject":"公告修正本公司113年度股東會年報部分內容","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-09-05 16:40，「公告修正本公司113年度股東會年報部分內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2025-09-05-1539-e69bq6","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2025-09-05","time":"15:39:30","subject":"(補公告)董事會決議通過本公司對美國子公司增資案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2025-09-05 15:39，「(補公告)董事會決議通過本公司對美國子公司增資案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7803-2025-09-05-1457-1o3c9qs","company_id":"7803","company":"雲象科技-創","market":"上市","industry":"生技醫療","date":"2025-09-05","time":"14:57:07","subject":"公告本公司第一屆審計委員會委員異動","clause":"第6款","fact_date":"2025-09-05","cite_as":"公開資訊觀測站重大訊息：雲象科技-創（7803），2025-09-05 14:57，「公告本公司第一屆審計委員會委員異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7803-2025-09-05-1456-13pln9r","company_id":"7803","company":"雲象科技-創","market":"上市","industry":"生技醫療","date":"2025-09-05","time":"14:56:28","subject":"本公司114年第二次股東臨時會通過解除董事競業禁止之限制案","clause":"第22款","fact_date":"2025-09-05","cite_as":"公開資訊觀測站重大訊息：雲象科技-創（7803），2025-09-05 14:56，「本公司114年第二次股東臨時會通過解除董事競業禁止之限制案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7803-2025-09-05-1455-dgnz4c","company_id":"7803","company":"雲象科技-創","market":"上市","industry":"生技醫療","date":"2025-09-05","time":"14:55:48","subject":"公告本公司114年第二次股東臨時會補選獨立董事3席當選名單暨董事變動達三分之一","clause":"第6款","fact_date":"2025-09-05","cite_as":"公開資訊觀測站重大訊息：雲象科技-創（7803），2025-09-05 14:55，「公告本公司114年第二次股東臨時會補選獨立董事3席當選名單暨董事變動達三分之一」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7803-2025-09-05-1454-2gra8h","company_id":"7803","company":"雲象科技-創","market":"上市","industry":"生技醫療","date":"2025-09-05","time":"14:54:36","subject":"公告本公司114年第2次股東臨時會重要決議事項","clause":"第15款","fact_date":"2025-09-05","cite_as":"公開資訊觀測站重大訊息：雲象科技-創（7803），2025-09-05 14:54，「公告本公司114年第2次股東臨時會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6523-2025-09-05-1409-s364tb","company_id":"6523","company":"達爾膚","market":"上櫃","industry":"生技醫療","date":"2025-09-05","time":"14:09:21","subject":"公告本公司訂定除息基準日","clause":"第14款","fact_date":"2025-09-05","cite_as":"公開資訊觀測站重大訊息：達爾膚（6523），2025-09-05 14:09，「公告本公司訂定除息基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4168-2025-09-05-1403-1izwmma","company_id":"4168","company":"醣聯","market":"上櫃","industry":"生技醫療","date":"2025-09-05","time":"14:03:33","subject":"公告本公司114年現金增資認股基準日等相關事宜","clause":"第11款","fact_date":"2025-09-05","cite_as":"公開資訊觀測站重大訊息：醣聯（4168），2025-09-05 14:03，「公告本公司114年現金增資認股基準日等相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6492-2025-09-05-1341-wqhhip","company_id":"6492","company":"生華科","market":"上櫃","industry":"生技醫療","date":"2025-09-05","time":"13:41:14","subject":"生華科新藥CX-5461獲選美國NCI-NExT五年抗癌計畫的第二項臨床試驗，用在治療具特定MYC基因變異的B細胞淋巴瘤第1b/2期人體試驗已獲美國FDA核准執行。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：生華科（6492），2025-09-05 13:41，「生華科新藥CX-5461獲選美國NCI-NExT五年抗癌計畫的第二項臨床試驗，用在治療具特定MYC基因變異的B細胞淋巴瘤」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}